Timothy Eugene Sullivan Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Timothy Eugene Sullivan is Chief Financial Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 152,041 shares of APLS, which is worth approximately $3.09 Million. The most recent transaction as insider was on Nov 30, 2023, when has been sold 14,158 shares (Common Stock) at a price of $10.03 per share, resulting in proceeds of $142,004. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 152K

37.05% 3M change

18.17% 12M change

Total Value Held $3.09 Million

Timothy Eugene Sullivan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 30 2023	BUY Exercise of conversion of derivative security	$142,004 $10.03 p/Share	14,158 Added 13.35%	91,871 Common Stock
Jul 03 2023	SELL Open market or private sale	$612,211 $90.31 p/Share	6,779 Reduced 8.02%	77,713 Common Stock
Jul 03 2023	BUY Exercise of conversion of derivative security	$67,993 $10.03 p/Share	6,779 Added 7.43%	84,492 Common Stock
Jun 05 2023	SELL Open market or private sale	$6,220,797 $89.15 p/Share	69,779 Reduced 47.31%	77,713 Common Stock
Jun 05 2023	BUY Exercise of conversion of derivative security	$699,883 $10.03 p/Share	69,779 Added 32.12%	147,492 Common Stock
May 03 2023	SELL Bona fide gift	-	20,000 Reduced 20.47%	77,713 Common Stock
Apr 19 2023	SELL Bona fide gift	-	36,232 Reduced 27.05%	97,713 Common Stock

Feb 21 2023	SELL Payment of exercise price or tax liability	$56,979 $58.5 p/Share	974 Reduced 0.72%	133,945 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	11,683 Added 7.97%	134,919 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$49,929 $51.21 p/Share	975 Reduced 0.78%	123,236 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$29,076 $52.77 p/Share	551 Reduced 0.44%	124,211 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$123,826 $52.05 p/Share	2,379 Reduced 1.87%	124,762 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	27,488 Added 17.78%	127,141 Common Stock
Apr 25 2022	SELL Other acquisition or disposition	-	3,750 Reduced 3.63%	99,653 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$41,230 $47.12 p/Share	875 Reduced 0.84%	103,403 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$25,084 $38.59 p/Share	650 Reduced 0.62%	104,278 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	30,787 Added 22.69%	104,928 Common Stock
Jun 08 2021	BUY Exercise of conversion of derivative security	$399,996 $10.03 p/Share	39,880 Added 34.98%	74,141 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$40,944 $47.72 p/Share	858 Reduced 2.44%	34,261 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	11,250 Added 24.26%	35,119 Common Stock

TES

Timothy Eugene Sullivan

Chief Financial Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account